JP6262246B2 - ベンダムスチン誘導体およびこれを使用する方法 - Google Patents

ベンダムスチン誘導体およびこれを使用する方法 Download PDF

Info

Publication number
JP6262246B2
JP6262246B2 JP2015541995A JP2015541995A JP6262246B2 JP 6262246 B2 JP6262246 B2 JP 6262246B2 JP 2015541995 A JP2015541995 A JP 2015541995A JP 2015541995 A JP2015541995 A JP 2015541995A JP 6262246 B2 JP6262246 B2 JP 6262246B2
Authority
JP
Japan
Prior art keywords
bendamustine
mmol
ester
solid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015541995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015536996A5 (OSRAM
JP2015536996A (ja
Inventor
バカレ、ロジャー、ピー．
ブラウン、ピーター、ディー．
チェン、ジアン
ドレーガー、アンソニー、エス．
レーベル、レイチェル、ワイ．
マッキーン、ロバート、イー．
パテル、ピユシュ、アール．
ローメリー、レネイ、シー．
Original Assignee
イグニタ、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イグニタ、インク． filed Critical イグニタ、インク．
Publication of JP2015536996A publication Critical patent/JP2015536996A/ja
Publication of JP2015536996A5 publication Critical patent/JP2015536996A5/ja
Application granted granted Critical
Publication of JP6262246B2 publication Critical patent/JP6262246B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015541995A 2012-11-12 2013-11-12 ベンダムスチン誘導体およびこれを使用する方法 Expired - Fee Related JP6262246B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US61/725,213 2012-11-12
US201361776951P 2013-03-12 2013-03-12
US61/776,951 2013-03-12
PCT/US2013/069550 WO2014075035A1 (en) 2012-11-12 2013-11-12 Bendamustine derivatives and methods of using same

Publications (3)

Publication Number Publication Date
JP2015536996A JP2015536996A (ja) 2015-12-24
JP2015536996A5 JP2015536996A5 (OSRAM) 2016-12-28
JP6262246B2 true JP6262246B2 (ja) 2018-01-17

Family

ID=49667594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015541995A Expired - Fee Related JP6262246B2 (ja) 2012-11-12 2013-11-12 ベンダムスチン誘導体およびこれを使用する方法

Country Status (17)

Country Link
US (7) US9452988B2 (OSRAM)
EP (1) EP2917183A1 (OSRAM)
JP (1) JP6262246B2 (OSRAM)
KR (1) KR20150086308A (OSRAM)
AR (1) AR093457A1 (OSRAM)
AU (1) AU2013342015B2 (OSRAM)
BR (1) BR112015010501A2 (OSRAM)
CA (1) CA2890462A1 (OSRAM)
CL (1) CL2015001246A1 (OSRAM)
EA (1) EA029706B1 (OSRAM)
HK (2) HK1212977A1 (OSRAM)
IL (1) IL238662A (OSRAM)
MX (1) MX2015005805A (OSRAM)
PH (1) PH12015501024A1 (OSRAM)
SG (1) SG11201503560TA (OSRAM)
TW (1) TWI598341B (OSRAM)
WO (1) WO2014075035A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
EP2917183A1 (en) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
EP2968153B1 (en) 2013-03-12 2018-05-02 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
RS61485B1 (sr) 2015-07-16 2021-03-31 Array Biopharma Inc Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze
US11071789B2 (en) * 2016-07-13 2021-07-27 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3224945C (en) 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
AU2002239405A1 (en) 2000-12-01 2002-06-11 Enzon, Inc. Tetrapartate prodrugs
AU2003227147A1 (en) * 2002-04-05 2003-10-27 Universite De Montreal Stealthy polymeric biodegradable nanospheres and uses thereof
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN103285395A (zh) 2005-02-18 2013-09-11 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
EP2222278B1 (en) 2007-11-28 2015-04-08 Celator Pharmaceuticals, Inc. Improved taxane delivery system
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
EP2889029A1 (en) 2008-09-25 2015-07-01 Cephalon, Inc. Liquid formulations of bendamustine
US9149441B2 (en) * 2008-09-29 2015-10-06 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
EP2346836B1 (en) * 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine
NZ592970A (en) * 2008-12-03 2013-05-31 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
JP6209446B2 (ja) 2010-06-02 2017-10-04 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
WO2012059935A1 (en) 2010-11-01 2012-05-10 Shilpa Medicare Limited Process for preparing bendamus tine hydrochloride monohydrate
DE102010055499A1 (de) * 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
HRP20200793T1 (hr) 2011-05-09 2020-10-16 Mayo Foundation For Medical Education And Research Liječenje raka
US9308276B2 (en) 2011-05-17 2016-04-12 University Of South Alabama Combination therapy for treatment of cancer
EP2760842B1 (en) 2011-09-26 2016-11-16 Fresenius Kabi Oncology Ltd An improved process for the preparation of bendamustine hydrochloride
EP2656843B1 (en) 2012-04-26 2015-03-18 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
CA2875455C (en) 2012-06-19 2020-03-10 Helmut Schickaneder Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy
AU2013299641A1 (en) 2012-08-10 2015-03-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
EP2917183A1 (en) 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same

Also Published As

Publication number Publication date
US9913827B2 (en) 2018-03-13
US20170182008A1 (en) 2017-06-29
US20150246023A1 (en) 2015-09-03
IL238662A0 (en) 2015-06-30
HK1212977A1 (zh) 2016-06-24
US20160016912A1 (en) 2016-01-21
US20160289198A1 (en) 2016-10-06
IL238662A (en) 2017-08-31
BR112015010501A2 (pt) 2017-07-11
AU2013342015A1 (en) 2015-05-28
US20150274675A1 (en) 2015-10-01
EA029706B1 (ru) 2018-05-31
SG11201503560TA (en) 2015-06-29
TW201439069A (zh) 2014-10-16
CA2890462A1 (en) 2014-05-15
PH12015501024A1 (en) 2015-07-27
KR20150086308A (ko) 2015-07-27
US9150517B2 (en) 2015-10-06
HK1215701A1 (zh) 2016-09-09
US20150232427A1 (en) 2015-08-20
CL2015001246A1 (es) 2016-01-15
TWI598341B (zh) 2017-09-11
AU2013342015B2 (en) 2016-11-24
EA201590925A1 (ru) 2015-09-30
US9149464B2 (en) 2015-10-06
JP2015536996A (ja) 2015-12-24
MX2015005805A (es) 2016-04-15
EP2917183A1 (en) 2015-09-16
US9452988B2 (en) 2016-09-27
US20180147186A1 (en) 2018-05-31
AR093457A1 (es) 2015-06-10
CN105051016A (zh) 2015-11-11
US9630926B2 (en) 2017-04-25
WO2014075035A1 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
JP6262246B2 (ja) ベンダムスチン誘導体およびこれを使用する方法
US20110040113A1 (en) Pure PEG-lipid conjugates
US10463743B2 (en) Amphiphilic drug-drug conjugates for cancer therapy, compositions and methods of preparation and uses thereof
JP2015512938A (ja) 安定なミセルのためのブロックコポリマー
JP2016511222A (ja) ポルフィリン修飾されたテロデンドリマー
AU2006202613A1 (en) Taxane Prodrugs
JP2003525282A (ja) 診断および治療用の新規キノリン配位子および金属錯体
WO2012103328A1 (en) Labeled, non- peptidic multivalent integrin alpha -v - beta - 3 antagonists, compositions containing them and their use
RU2721949C2 (ru) Модифицированные цитотоксины и их терапевтическое применение
US20210346518A1 (en) Cyanine-based telodendrimers and uses for treating cancer
CN111344018A (zh) 聚乙二醇化卡非佐米化合物的稳定的组合物
US20130203647A1 (en) Delivery of hydrophilic peptides
WO2011139343A2 (en) Amino acid linked peg-lipid conjugates
Li et al. Intramuscularly injected long-acting testosterone-cholesterol prodrug suspension with three different particle sizes: extended in vitro release and enhanced in vivo safety
CN105051016B (zh) 苯达莫司汀衍生物及其使用方法
Xu et al. Cascade-responsive nanoplatform for synergistic cancer therapy via ROS amplification and hypoxia targeting
US20160143914A1 (en) Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof
Sun A Sequential Stimulus-Responsive Nanoparticle Platform for Enhanced Tumor Growth Inhibition and Efficient Drug Delivery
WO2023222659A1 (en) Trehalose-based surfactants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161111

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171213

R150 Certificate of patent or registration of utility model

Ref document number: 6262246

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees